Scientific advances in cardiovascular research during the last decades have afforded effective pharmacological treatment to those surviving their first acute myocardial infarction. This secondary prevention treatment, based upon the combined administration of statins, aspirin, beta-blockers and renin-angiotensin blockers, might avert great part of the relapses contributing substantially to the overall incidence of acute coronary syndromes in the general population. However, a treatment gap separates evidence-based recommendations from their daily clinical application, a condition frequently explored even in the Italian medical setting. However, a general overview of the problem is missing insofar, a contribution that might eventually help to improve the status of secondary coronary prevention in our national environment
Pedrinelli, R., Ciccone, M., Novo, S., Catapano, A.L. (2012). [Pharmacological prevention of coronary relapses in Italian clinical practice: a literature review]. La prevenzione farmacologica delle recidive coronariche nella pratica clinica Italiana: Una revisione della letteratura. GIORNALE ITALIANO DI CARDIOLOGIA, 13(11), 734-740 [10.1714/1168.12949].
[Pharmacological prevention of coronary relapses in Italian clinical practice: a literature review]. La prevenzione farmacologica delle recidive coronariche nella pratica clinica Italiana: Una revisione della letteratura
NOVO, Salvatore;
2012-01-01
Abstract
Scientific advances in cardiovascular research during the last decades have afforded effective pharmacological treatment to those surviving their first acute myocardial infarction. This secondary prevention treatment, based upon the combined administration of statins, aspirin, beta-blockers and renin-angiotensin blockers, might avert great part of the relapses contributing substantially to the overall incidence of acute coronary syndromes in the general population. However, a treatment gap separates evidence-based recommendations from their daily clinical application, a condition frequently explored even in the Italian medical setting. However, a general overview of the problem is missing insofar, a contribution that might eventually help to improve the status of secondary coronary prevention in our national environmentFile | Dimensione | Formato | |
---|---|---|---|
pharmacological prevention.pdf
accesso aperto
Dimensione
525.48 kB
Formato
Adobe PDF
|
525.48 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.